TD Private Client Wealth LLC Buys 14,533 Shares of Merck & Co., Inc. $MRK

TD Private Client Wealth LLC increased its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 59.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 39,014 shares of the company’s stock after acquiring an additional 14,533 shares during the quarter. TD Private Client Wealth LLC’s holdings in Merck & Co., Inc. were worth $4,107,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. D.A. Davidson & CO. increased its holdings in Merck & Co., Inc. by 4.4% in the 4th quarter. D.A. Davidson & CO. now owns 576,959 shares of the company’s stock valued at $60,731,000 after buying an additional 24,576 shares during the period. Farther Finance Advisors LLC increased its holdings in Merck & Co., Inc. by 48.9% in the 4th quarter. Farther Finance Advisors LLC now owns 97,818 shares of the company’s stock valued at $10,296,000 after buying an additional 32,114 shares during the period. Coldstream Capital Management Inc. increased its holdings in Merck & Co., Inc. by 12.7% in the 3rd quarter. Coldstream Capital Management Inc. now owns 123,366 shares of the company’s stock valued at $10,364,000 after buying an additional 13,940 shares during the period. NEOS Investment Management LLC increased its holdings in Merck & Co., Inc. by 39.9% in the 3rd quarter. NEOS Investment Management LLC now owns 347,684 shares of the company’s stock valued at $29,181,000 after buying an additional 99,074 shares during the period. Finally, Campbell Capital Management Inc. bought a new stake in Merck & Co., Inc. in the 3rd quarter valued at $1,866,000. Institutional investors own 76.07% of the company’s stock.

Analyst Ratings Changes

Several brokerages have issued reports on MRK. Wells Fargo & Company lowered their price target on shares of Merck & Co., Inc. from $150.00 to $145.00 and set an “overweight” rating on the stock in a report on Friday, May 1st. UBS Group boosted their price target on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the company a “buy” rating in a report on Monday, April 13th. Weiss Ratings lowered shares of Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a report on Friday. Wall Street Zen lowered shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating in a report on Saturday. Finally, Royal Bank Of Canada reissued an “outperform” rating and issued a $142.00 price target on shares of Merck & Co., Inc. in a report on Monday, March 30th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and seven have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $128.18.

Merck & Co., Inc. Stock Up 1.1%

Shares of NYSE MRK opened at $112.63 on Tuesday. The firm’s 50-day simple moving average is $115.94 and its 200 day simple moving average is $109.54. The company has a market cap of $278.18 billion, a price-to-earnings ratio of 31.73, a price-to-earnings-growth ratio of 2.51 and a beta of 0.18. The company has a quick ratio of 1.06, a current ratio of 1.30 and a debt-to-equity ratio of 1.02. Merck & Co., Inc. has a 12-month low of $75.40 and a 12-month high of $125.14.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.47) by $0.19. The business had revenue of $16.29 billion for the quarter, compared to the consensus estimate of $15.85 billion. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The firm’s quarterly revenue was up 4.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.22 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, research analysts expect that Merck & Co., Inc. will post 5.16 earnings per share for the current fiscal year.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.